Drug intelligence / Profile preview

cisplatin + fluorouracil + interleukin-2

Development stage: Unknown
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous

Overview

A combination chemotherapy and immunotherapy regimen consisting of cisplatin, fluorouracil (5-FU), and interleukin-2 (IL-2). Cisplatin is a platinum-based chemotherapy agent that forms DNA adducts, interfering with DNA replication and transcription. Fluorouracil is a pyrimidine analog that acts as an antimetabolite, disrupting DNA and RNA synthesis in rapidly dividing cells. Interleukin-2 is an immunotherapeutic agent that stimulates T-cell proliferation and activation. This combination leverages both direct cytotoxic effects on cancer cells and immune system stimulation to target tumors.

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)DNATS (Thymidylate synthase)

Beyond the preview

Go deeper on cisplatin + fluorouracil + interleukin-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + fluorouracil + interleukin-2.

Explore the full profile